GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
The conversation is about a person using minoxidil, finasteride, estrogen, and bicalutamide to combat hair loss, expressing frustration and desperation over their situation. They are advised against using female hormones and encouraged to focus on finasteride and minoxidil, with suggestions to seek therapy for mental health support.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Cyproterone Acetate stopped hair loss and led to regrowth on the temples for a transgender individual, which is considered a good sign. Unlike Minoxidil and Finasteride, which can cause initial shedding, Cyproterone did not cause shedding.
The user shares their experience with hair loss treatments, specifically finasteride, and discusses the side effects like lowered libido and motivation. They recommend trying tyrosine to counter these effects, noting it improved their libido and energy levels.
The conversation discusses using Tribulus Terrestris and Zinc to boost libido while on finasteride, with some users reporting success in increasing libido despite no testosterone boost. The original poster also considers reducing finasteride dosage and using Cialis for libido and bodybuilding purposes.
A user shared their successful experience with hair regrowth and transitioning from male to female using minoxidil, finasteride, Nutrafol, microneedling, and hormone replacement therapy (HRT). They expressed gratitude for the results and encouraged others to explore treatments that align with their personal goals.
Theaflavin, a black tea extract, may inhibit DHT and androgen receptor activity, but its effectiveness for hair loss is debated. Users report no significant improvement with theaflavin, while some find beta sitosterol helpful.
User experienced high E2 levels after taking finasteride and sought advice on lowering E2 with supplements like Tonkat ali, Fadogia, and Boron. They also used DIM, zinc, and magnesium but avoided using an AI.
The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
The user is experiencing hair loss and is using finasteride while addressing low ferritin and copper levels. They are concerned about continued hair shedding and are advised to correct vitamin deficiencies and wait for finasteride results after 12 months.
The user has been on 1mg finasteride for a year, experiencing low libido and moderate erectile issues. They are considering using Cialis daily with finasteride long term to address these side effects.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
A user is considering ordering topical finasteride with castor and rosemary oil from a Turkish pharmacy. They are debating whether to include the oils or use only PG and ethanol as the carrier.
The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
The conversation discusses hair loss treatments including finasteride, minoxidil, derma rolling, and tretinoin, with the user showing progress after five months. Tretinoin is mentioned to enhance the effectiveness of minoxidil.
The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.
User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.